Breaks Categories: News

ThursdayJul 29, 2021 9:50 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Third Quarter Numbers, Notes Q3 Investor Day

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, has reported its interim financial results; the results cover the three- and nine-month period ended May 31, 2021. Highlights of the report include Tryp’s collaboration with the Chronic Pain & Fatigue Research Center at the University of Michigan Medical School; the two companies will work together to conduct a Phase 2a clinical trial for fibromyalgia that is the first Phase 2 study evaluating the efficacy of a psychedelic compound for the indication. In addition, Tryp also partnered with the…

Continue Reading

ThursdayJul 29, 2021 9:49 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has received approval for its common shares to trade on the NYSE American LLC stock exchange. According to the announcement, the company anticipates that trading to begin on or about Aug. 5, 2021; the company will trade on the exchange using the symbol CYBN. The company will continue to list its common shares in Canada on the NEO Exchange under the symbol CYBN and on the Frankfurt Stock Exchange under the symbol R7E1. Shareholders are encouraged to check their accounts to make sure that change in exchange…

Continue Reading

MondayJul 26, 2021 1:20 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Board Appointments

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced the appointment of Robin Carhart-Harris, Ph.D. as chairman of Tryp’s Scientific Advisory Board (“SAB”) and Daniel Clauw, M.D. as a new member of the SAB. Dr. Carhart-Harris initially joined Tryp’s SAB in February 2021 and has been instrumental in advising the company through the development of its Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program. Dr. Clauw is a world-leading expert in fibromyalgia and other nociplastic pain indications. “With today’s announcement, I would like to thank Dr. Robin…

Continue Reading

ThursdayJul 22, 2021 1:10 pm

PsychedelicNewsBreaks – Microdose Psychedelic Insights Shares Agenda Information for Psychedelic Capital: July 2021 Conference

Microdose Psychedelic Insights, a cutting-edge media company focused around promoting content, financial analysis and events designed to drive the psychedelics industry into the forefront of modern medicine, has announced information about its Psychedelic Capital: July 2021 conference. The all-virtual event is scheduled for July 29, 2021 and is designed to shine the spotlight on some of the industry’s top companies, latest IPOs and newest opportunities; the conference presentations also provide deep insights into relevant and timely industry topics. Included in the conference is a focus on psychedelic medicine investment, which includes opportunities for investors and attendees to interact with a…

Continue Reading

WednesdayJul 21, 2021 10:24 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), University of Michigan to Collaborate in Phase 2a Clinical Trial for Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced its plans to conduct a phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School. According to the update, the open-label trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia. The treatment is designed to leverage the neuroplasticity benefits of psilocybin to target nociplastic pain originating in the central…

Continue Reading

TuesdayJul 20, 2021 11:02 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Definitive Agreement to Acquire 3a-Diagnostics

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, has signed a definitive agreement to acquire its exclusive diagnostics development partner 3a-diagnostics GmbH, Frickenhausen, Germany. Per the terms of the definitive agreement, XPhyto will acquire all outstanding shares of 3a for EUR 400,000, to be paid immediately, and EUR 3.5 million, to be paid on closing, which is anticipated to take place on or around October 31, 2021. This acquisition will create considerable commercial development and manufacturing opportunities for XPhyto, in addition to providing improved margins on its diagnostic products. “We have collaborated closely with the 3a-diagnostics…

Continue Reading

ThursdayJul 15, 2021 12:20 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Upcoming Q3 Investor Day

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, will be hosting a third-quarter virtual Investor Day. The company has scheduled this event for July 29, 2021; it will begin at 9 a.m. PDT. Included on the event agenda will be a presentation by Tryp’s management team. The presentation will provide updates regarding the company’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program. The team will also discuss 2021 milestones. In addition, the agenda features a Q&A session. Tryp executives participating in the event include Greg McKee,…

Continue Reading

TuesdayJul 13, 2021 9:47 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent as Part of Digital Therapeutics Strategy

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has filed a new provisional patent application to protect its proprietary digital therapeutics platform; the patent is the company’s 13th. In addition, the company is also advancing the build-out of its digital therapeutics strategy, with the objective of evolving its programs beyond the psychedelic molecule into an eco-system with potential to improve patient treatments. A newly formed patient steering company is part of the company’s focus on its digital therapeutics platform, designed to better support the evaluation of patient outcomes through a highly secure, patient-centered data analytics…

Continue Reading

TuesdayJul 13, 2021 9:41 am

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Files Two Patents for Fully Synthetic Routes to Create Ibogaine Psychedelic Compound

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has filed two provisional patent applications with the United States Patent and Trademark Office (“USPTO”) for innovative processes for synthesizing ibogaine. According to the announcement, MINDCURE’s pharmaceutical-grade ibogaine would provide researchers access to a sustainable, high-quality, reliable and consistent supply of the psychedelic drug, ibogaine. The company is currently evaluating which of the two processes to develop first. MCURF has already completed the first stage of manufacturing pharmaceutical-grade ibogaine to be used in clinical research and is now preparing to begin stage…

Continue Reading

FridayJul 09, 2021 9:32 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Notes European Expansion, IP Portfolio Updates, to Participate in Neuropsychiatry Virtual Summit

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is increasing its focus and research activities in Europe. The company announced that it is working with several academic and clinical research organizations as part of those efforts, which include the transfer of its intellectual property assets to its recently formed wholly owned Ireland subsidiary. According to the announcement, Cybin will also continue building its IP portfolio of novel psychedelic compounds, delivery platforms and methods of use in psychiatric indications. The company noted that its growing portfolio of intellectual property includes 12 patent filings and four active…

Continue Reading